Abzena has secured $65 million in additional funding to expand its production facilities to meet the increased demand in the industry. Contract development manufacturing organization (CDMO) Abzena says the latest investment from Welsh, Carson, Anderson & Stowe, and Biospring Partners will allow the firm to meet growing demand by increasing the capacity of its manufacturing capabilities for clinical and commercial supply. “At Abzena, we put patients at the center of all that we do. This new capital will allow us…

Bayer says a three-year production reorganization will modernize its manufacturing network and streamline its supply chain, but specific details remain scarce. The Germany-headquartered biopharma firm announced “it is strengthening the production network of its pharmaceutical division” yesterday through a three-year, €2 billion ($2.2 billion) restructure plan. According to the release, “Bayer is planning to invest in its core manufacturing plants and strengthen their operational responsibilities to sustainably support the implementation of the company’s strategy for its pharmaceuticals business. A significant…

The CDMO has expanded its facilities by a further 22,600 square feet to relieve its capacity constraints. Contract development and manufacturing organization (CDMO) Exothera was founded in March 2020 by Belgium-based bioprocess tech firm Univercells, to offer cell and gene therapy developers process development and viral vector manufacturing. After expanding its two facilities in Jumet, Belgium about 25 km south of Brussels, and selecting bioprocess vendor Pall Corporation to equip the roughly 92,000 square feet of space in July 2021,…

eTheRNA Manufacturing introduces a lipid nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical advancement of RNA-based therapeutics and vaccines. According to the RNA technology firm, the LNP service uses eTheRNA’s lipid libraries and formulations to enable targeted delivery and tailored biodistribution solutions. Additionally, the service has been developed to allow customers to maximize the delivery of their RNA-products. “This service can cover product needs for early research and development and can be further optimized…

ten23 health will add 1000 square meters at its site in Visp, Switzerland by expanding into an adjacent building. The contract development manufacturing organization (CDMO) acquired its Visp, canton of Valais, Switzerland manufacturing site from swissfillon last October. Now, the firm will add 1,000 square meters of clean room space to enlarge its cold storage and visual inspection capacity. “ten23 health needs to increase the supporting infrastructure in order to utilize our assets for sterile production in Visp,” a spokesperson…

Wockhardt and Serum Life Sciences UK have partnered to build a facility in Wrexham, Wales to manufacture various vaccines. Wockhardt, headquartered in Mumbai, India said the collaboration with Serum Life Sciences UK (a subsidiary of the Serum Institute of India) will deliver an additional 150 million doses of a wide range of vaccines through building a fill-finish facility in Wrexham, North Wales. “We are delighted to have formed a strategic partnership between Wockhardt and Serum Life Sciences. The collaboration will…

Manufacturing of cancer drug Trodelvy will be moved to Oceanside, California as part of a restructuring of Gilead Science’s New Jersey operations. In September 2020, Gilead paid $21 billion to acquire Immunomedics. The deal added antibody-drug conjugate (ADC) Trodelvy (sacitizumab govitecan) – approved in April 2020 to treat triple negative breast cancer – to Gilead’s portfolio, along with an biomanufacturing facility in Morris Plains, New Jersey. But plans to create a corporate hub in Northern New Jersey will result in…

I Peace has invested over $10 million to expand its Palo Alto, California plant, tripling capacity to manufacture iPS and iPSC-derived differentiated cells. I Peace, a contract development manufacturing organization (CDMO) start-up, has tripled its capacity to produce induced pluripotent stem (iPS) cells and induced pluripotent stem cells (iPSC) by expanding its facility. The firm claims that the plant expansion will meet the demand for iPS cells from pharmaceutical companies and cell therapy manufacturers, as well as providing individuals with…

Catalent has expanded its Limoges, France site to fulfil clinical biologics formulation development and drug product fill/finish services. Contract development manufacturing organization (CDMO) Catalent announced its plans to invest $30 million in July 2020. Now, the firm has completed the project and says the Limoges plant will widen its global network, with clinical development through to clinical supply services and small-scale commercial manufacturing. “Catalent continues to look for ways to support its customers as they advance projects to the clinic…

Stevanato Group says its decision to acquire a facility in Zhangjiagang, China is part of its growth strategy and aim to deliver supply chain security. Stevanato, a provider of drug delivery, drug containment, and diagnostic solutions to the life sciences industry, has acquired a facility located close to its plant in the Jiangsu Zhangjiagang Economic and Technical Development Zone. “[Our] facility in Zhangjiagang will support the production of high-value solutions, such as pre-sterilized EZ-fill syringes and vials, meeting the growing…